According to a recent SEC filing, Chief Scientific Officer Stephen Betz sold 3,000 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) on August 12, 2024. Following this transaction, the insider now owns 72,611 shares of the company.

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Over the past year, Stephen Betz has sold a total of 36,000 shares and purchased no shares. This latest transaction continues a trend observed over the past year, when there were 35 insider sales and no insider purchases at Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc. shares were trading at $47.68 on the day of the transaction. The company has a market capitalization of approximately $4.12 billion.

Investors can find more detailed valuation metrics such as the GF Value, the price-earnings ratio, the price-sales ratio, the price-book ratio and the price-free cash flow ratio under the corresponding links.

This insider sale could be of interest to investors who track changes in ownership and evaluate the stock’s current valuation metrics.

This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.

This article first appeared on GuruFocus.